Cefepime
سفپیم
🦠 Antiinfectives For Systemic UseFourth-generation cephalosporin
Market / country: 🇺🇸 USA
Maxipime (US)
🧮 Dose calculator
Community-acquired pneumonia · Regimen source: FDA Cefepime · 2.1
- • Pseudomonas: 2 g every 8 h. The calculator shows 12-hourly. FDA Cefepime · 2.1
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Immediate hypersensitivity to cefepime, cephalosporins, penicillins or other beta-lactams. FDA Cefepime · 4
Warnings
- • Encephalopathy, myoclonus and non-convulsive status, mainly with renal impairment without dose adjustment; C. difficile diarrhoea. FDA Cefepime · 5
Renal adjustment
- • eGFR < 60: CrCl ≤60: reduce dose or extend interval per label table. FDA Cefepime · 2.3
Formulations
- 1 g vial — powder for injection 🇺🇸 USA FDA Cefepime · 3
- 2 g vial — powder for injection 🇺🇸 USA FDA Cefepime · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Cefepime · 8.1
“Risk Summary There are no cases of cefepime exposure during pregnancy reported from postmarketing experience or from clinical trials.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Cefepime · 8.2
“Risk Summary Cefepime is present in human breast milk at low concentrations (approximately 0.5 mcg/mL) following a single intravenous dose of 1000 mg.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Cefepime · 8.4
“The safety and effectiveness of cefepime in the treatment of uncomplicated and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin structure infections, pneumonia, and as empiric therapy for febrile neutropenic patients have been established in the age groups 2 months up to 16 …”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Cefepime · 8.5
“… ng life-threatening or fatal occurrences of the following: encephalopathy, myoclonus, and seizures [see Warnings and Precautions ( 5.2 ), Adverse Reactions ( 6.2 )] .”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA065441
- DailyMed (FDA label)FDA Cefepime
- MedlinePlus (NIH)Cefepime Injection
- WHO ATC/DDDJ01DE01
- Darooyab (Iran)Cefepime
🇮🇷 Registered in Iran Darooyab · G-323/Cefepime
Dosage forms with Iranian generic codes, per Darooyab.
- 02416 · CEFEPIME HYDROCHLORIDE 1 G VIAL · ویال سفپیم هیدروکلراید ۱ گرم
- 02417 · CEFEPIME HYDROCHLORIDE 2 G VIAL · ویال سفپیم هیدروکلراید ۲ گرم
- 02418 · CEFEPIME HYDROCHLORIDE 500MG VIAL · ویال سفپیم هیدروکلراید ۵۰۰ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Cefepime · 3FDA Cefepime · 2.1FDA Cefepime · 2.2FDA Cefepime · 4FDA Cefepime · 5FDA Cefepime · 2.3FDA Cefepime · 8.1FDA Cefepime · 8.2FDA Cefepime · 8.4FDA Cefepime · 8.5FDA Cefepime · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-323/Cefepime
- Clinical review⚠ Unverified